xRead - Episodic Vertigo (January 2026)

10976817, 2020, S2, Downloaded from https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1177/0194599820909438 by Mayo Clinic Libraries, Wiley Online Library on [19/09/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

S48

Otolaryngology–Head and Neck Surgery 162(2S)

163. Adams ME, Heidenreich KD, Kileny PR. Audiovestibular testing in patients with Me´nie`re’s disease. Otolaryngol Clin North Am . 2010;43(5):995-1009. 164. Adams ME, Marmor S, Yueh B, Kane RL. Geographic varia tion in use of vestibular testing among Medicare benefici aries. Otolaryngol Head Neck Surg . 2017;156(2):312-320. 165. Piker EG, Schulz K, Parham K, et al. Variation in the use of vestibular diagnostic testing for patients presenting to otolar yngology clinics with dizziness. Otolaryngol Head Neck Surg . 2016;155(1):42-47. 166. Phillips JS, Mallinson AI, Hamid MA. Cost-effective evalua tion of the vestibular patient. Curr Opin Otolaryngol Head Neck Surg . 2011;19(5):403-409. 167. Kelly EA, Stocker C, Kempton C, Dierking D, Fehlberg H, Adams M. Vestibular testing: patient perceptions, morbidity and opporunity costs. Otol Neurotol . 2018;39(10):1222-1228. 168. Ferraro JA, Durrant JD. Electrocochleography in the evalua tion of patients with Me´nie`re’s disease/endolymphatic hydrops. J Am Acad Audiol . 2006;17(1):45-68. 169. Foster CA, Breeze RE. Endolymphatic hydrops in Me´nie`re’s disease: cause, consequence, or epiphenomenon? Otol Neurotol . 2013;34(7):1210-1214. 170. Wuyts FL, Van De Heyning PH, Van Spaendonck MP, Molenberghs G. A review of electrocochleography: instru mentation settings and meta-analysis of criteria for diagnosis of endolymphatic hydrops. Acta Otolaryngol . 1997;117(suppl 526):14-20. 171. Ziylan F, Smeeing DP, Stegeman I, Thomeer HG. Click sti mulus electrocochleography versus MRI with intratympanic contrast in Me´nie`re’s disease: a systematic review. Otol Neurotol . 2016;37(5):421-427. 172. Iseli C, Gibson W. A comparison of three methods of using transtympanic electrocochleography for the diagnosis of Me´nie`re’s disease: click summating potential measurements, tone burst summating potential amplitude measurements, and biasing of the summating potential using a low frequency tone. Acta Otolaryngol . 2010;130(1):95-101. 173. Al-momani MO, Ferraro JA, Gajewski BJ, Ator G. Improved sensitivity of electrocochleography in the diagnosis of Me´nie`re’s disease. Int J Audiol . 2009;48(11):811-819. 174. Ikino CM, de Almeida ER. Summating potential-action potential waveform amplitude and width in the diagnosis of Me´nie`re’s disease. Laryngoscope . 2006;116(10):1766-1769. 175. Arts HA, Adams ME, Telian SA, El-Kashlan H, Kileny PR. Reversible electrocochleographic abnormalities in superior canal dehiscence. Otol Neurotol . 2009;30(1):79-86. 176. Cordero-Yanza JA, Arrieta Vazquez EV, Hernaiz Leonardo JC, Mancera Sanchez J, Hernandez Palestina MS, Perez Fernandez N. Comparative study between the caloric vestibu lar and the video-head impulse tests in unilateral Me´nie`re’s disease. Acta Otolaryngol . 2017;137(11):1178-1182. 177. Lee SU, Kim HJ, Koo JW, Kim JS. Comparison of caloric and head-impulse tests during the attacks of Me´nie`re’s dis ease. Laryngoscope . 2017;127(3):702-708. 178. Shin JE, Kim CH, Park HJ. Vestibular abnormality in patients with Me´nie`re’s disease and migrainous vertigo. Acta Otolaryngol . 2013;133(2):154-158.

149. Suga K, Kato M, Yoshida T, et al. Changes in endolymphatic hydrops in patients with Me´nie`re’s disease treated conserva tively for more than 1 year. Acta Otolaryngol . 2015;135(9): 866-870. 150. Fiorino F, Mattellini B, Vento M, Mazzocchin L, Bianconi L, Pizzini FB. Does the intravenous administration of frusemide reduce endolymphatic hydrops? J Laryngol Otol . 2016; 130(3):242-247. 151. Gurkov R, Flatz W, Keeser D, Strupp M, Ertl-Wagner B, Krause E. Effect of standard-dose betahistine on endolympha tic hydrops: an MRI pilot study. Eur Arch Otorhinolaryngol . 2013;270(4):1231-1235. 152. Sepahdari AR, Vorasubin N, Ishiyama G, Ishiyama A. endo lymphatic hydrops reversal following acetazolamide therapy: demonstration with delayed intravenous contrast-enhanced 3D-FLAIR MRI. Am J Neuroradiol . 2016;37(1):151-154. 153. Claes G, Van den Hauwe L, Wuyts F, Van de Heyning P. Does intratympanic gadolinium injection predict efficacy of gentamicin partial chemolabyrinthectomy in Me´nie`re’s dis ease patients? Eur Arch Otorhinolaryngol . 2012;269(2):413 418. 154. Fiorino F, Pizzini FB, Barbieri F, Beltramello A. Variability in the perilymphatic diffusion of gadolinium does not predict the outcome of intratympanic gentamicin in patients with Me´nie`re’s disease. Laryngoscope . 2012;122(4):907-911. 155. Fiorino F, Pizzini FB, Barbieri F, Beltramello A. Magnetic resonance imaging fails to show evidence of reduced endo lymphatic hydrops in gentamicin treatment of Me´nie`re’s dis ease. Otol Neurotol . 2012;33(4):629-633. 156. Liu F, Huang W, Chen Q, Meng X, Wang Z, He Y. Noninvasive evaluation of the effect of endolymphatic sac decompression in Me´nie`re’s disease using magnetic reso nance imaging. Acta Otolaryngol . 2014;134(7):666-671. 157. Liu IY, Sepahdari AR, Ishiyama G, Ishiyama A. High resolu tion MRI shows presence of endolymphatic hydrops in patients still symptomatic after endolymphatic shunt surgery. Otol Neurotol . 2016;37(8):1128-1130. 158. Uno A, Imai T, Watanabe Y, et al. Changes in endolymphatic hydrops after sac surgery examined by Gd-enhanced MRI. Acta Otolaryngol . 2013;133(9):924-929. 159. Zhang Y, Cui YH, Hu Y, et al. Changes in endolymphatic hydrops visualized by magnetic resonance imaging after sac surgery. J Huazhong Univ Sci Technolog Med Sci . 2016;36(5): 736-740. 160. Shellock F. Reference Manual for Magnetic Resonance Saftey, Implants, and Devices . Playa Del Rey, CA: Biomedical Research Publishing Group; 2018. 161. US Food and Drug Administration. FDA drug safety commu nication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warn ings. https://www.fda.gov/drugs/drug-safety-and-availability/ fda-drug-safety-communication-fda-warns-gadolinium-based contrast-agents-gbcas-are-retained-body. Published 2018. Accessed June 25, 2019. 162. US Food and Drug Administration. Magnevist for Intravenous Administration . Washington, DC: US Food and Drug Adminis tration; 2013.